Related Experiment Video
Updated: May 28, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for
1Department of Pharmaceutics, Changhai Hospital, Second Military Medical University, Shanghai.
Background:
The increased incidence of malignant melanoma in recent decades, along with its high mortality rate and pronounced resistance to therapy pose an enormous challenge. Novel therapeutic strategies, such as immunotherapy and targeted therapy, are urgently needed for melanoma. In this study, a new active targeting drug delivery system was constructed to combine chemotherapy and active specific immunotherapy.
Methods:
The chemotherapeutic drug, dacarbazine (DTIC), that induces apoptosis through the intrinsic pathway which typically responds to severe DNA damage, was used as a model drug to prepare DTIC-loaded polylactic acid (PLA) nanoparticles (DTIC-NPs), which were covalently conjugated to a highly specific targeting functional TRAIL-receptor 2 (DR5) monoclonal antibody (mAb) that can contribute directly to cancer cell apoptosis or growth inhibition through the extrinsic pathway.
Results:
Our in vitro experiments demonstrated that DTIC-PLA-DR5 mAb nanoparticles (DTIC-NPs-DR5 mAb) are an active targeting drug delivery system which can specifically target DR5-overexpressing malignant melanoma cells and become efficiently internalized. Most strikingly, compared with conventional DTIC-NPs, DTIC-NPs-DR5 mAb showed significantly enhanced cytotoxicity and increased cell apoptosis in DR5-positive malignant melanoma cells.
Conclusion:
The DTIC-NPs-DR5 mAb described in this paper might be a potential formulation for targeting chemotherapy and immunotherapy to DR5-overexpressing metastatic melanoma.
Insights
This study developed novel nanoparticles combining chemotherapy and immunotherapy to target melanoma. The new drug delivery system, DTIC-NPs-DR5 mAb, effectively killed melanoma cells overexpressing DR5, showing enhanced cytotoxicity.
Area of Science:
- Oncology
- Nanotechnology
- Immunotherapy
Background:
- Malignant melanoma incidence and mortality are rising, with significant therapeutic resistance.
- Novel strategies like immunotherapy and targeted therapy are crucial for melanoma treatment.
- This study introduces a novel active targeting drug delivery system combining chemotherapy and immunotherapy.
Purpose of the Study:
- To develop and evaluate a novel nanoparticle system for targeted melanoma therapy.
- To combine the chemotherapeutic dacarbazine (DTIC) with active specific immunotherapy targeting DR5.
Main Methods:
- Prepared DTIC-loaded polylactic acid (PLA) nanoparticles (DTIC-NPs).
- Conjugated DTIC-NPs with a monoclonal antibody (mAb) targeting TRAIL-receptor 2 (DR5) to create DTIC-NPs-DR5 mAb.
- Evaluated in vitro targeting, internalization, cytotoxicity, and apoptosis in DR5-overexpressing melanoma cells.
Main Results:
- DTIC-NPs-DR5 mAb actively targeted and were efficiently internalized by DR5-overexpressing melanoma cells.
- DTIC-NPs-DR5 mAb demonstrated significantly enhanced cytotoxicity compared to conventional DTIC-NPs.
- Increased apoptosis was observed in DR5-positive malignant melanoma cells treated with DTIC-NPs-DR5 mAb.
Conclusions:
- The developed DTIC-NPs-DR5 mAb system shows potential for targeted chemotherapy and immunotherapy in metastatic melanoma.
- This formulation may offer a new therapeutic approach for DR5-overexpressing melanoma.
- Further research could validate this system for clinical application in melanoma treatment.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...